Baker Brothers Life Sciences LP

Director, 10% OwnerNeoleukin Therapeutics, Inc. (NLTX) · full profile →Form 4 · filed Aug 17, 2023
Net Buying
Open-Market Buys
$1.5M
Open-Market Sells
$0
Net Open-Market Flow
$1.5M
Transactions
12
12 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 17, 2023Buy(P)5K$0.69$3K494K
Aug 17, 2023Buy(P)8K$0.69$5K489K
Aug 17, 2023Buy(P)61K$0.69$42K5.6M
Aug 17, 2023Buy(P)93K$0.69$64K5.6M
Aug 16, 2023Buy(P)4K$0.68$3K5.5M
Aug 16, 2023Buy(P)17K$0.68$12K481K
Aug 16, 2023Buy(P)208K$0.68$141K5.5M
Aug 16, 2023Buy(P)366$0.68$249481K
Aug 15, 2023Buy(P)144K$0.63$90K464K
Aug 15, 2023Buy(P)4K$0.67$3K5.2M
Aug 15, 2023Buy(P)1.7M$0.63$1.1M5.2M
Aug 15, 2023Buy(P)358$0.67$240464K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-046351) within minutes of acceptance. Every field above traces to the original document. Verify it directly: